Abstract
Atherosclerotic cardiovascular disease is a leading cause of death in much of the world. Adoption of a healthy lifestyle and cholesterol lowering are the key measures used to prevent major complications of atherosclerosis. Recent data have identified a critical role for inflammation mediated through activation of both innate and adaptive immune pathways in the pathophysiology of atherosclerosis opening up opportunities for development of anti-inflammatory interventions that could supplement risk factor modification and lipid lowering as an approach to further reducing the burden of atherosclerotic cardiovascular disease.
Keywords:
Atherosclerosis; Vascular inflammation.
Copyright © 2019. Published by Elsevier Inc.
MeSH terms
-
Animals
-
Anti-Infective Agents / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use
-
Atherosclerosis / diagnosis
-
Atherosclerosis / drug therapy
-
Atherosclerosis / epidemiology*
-
Atherosclerosis / immunology
-
Communicable Diseases / diagnosis
-
Communicable Diseases / drug therapy
-
Communicable Diseases / epidemiology*
-
Communicable Diseases / immunology
-
Gastrointestinal Microbiome
-
Host-Pathogen Interactions
-
Humans
-
Hypolipidemic Agents / therapeutic use
-
Inflammation / diagnosis
-
Inflammation / drug therapy
-
Inflammation / epidemiology*
-
Inflammation / immunology
-
Inflammation Mediators / immunology
-
Risk Assessment
-
Risk Factors
Substances
-
Anti-Infective Agents
-
Anti-Inflammatory Agents
-
Hypolipidemic Agents
-
Inflammation Mediators